Those results are better than what was avhieved by the only FDA Kras approved drug. They now have a target cancer to expand the trial on. Patient life expectency and disease none peogression period both significantly longer.
This is an awesome result.
The drug to be focused on cancers where it proved to be more effective by 30% plus on the FDA approved drug. So PTX 100 has worked 30% plus more effectively, and with a better safety profile.
Surprising market reaction.
Ann: PTX-100 trial advances following successful Phase 1b, page-66
-
- There are more pages in this discussion • 341 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
